Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage.
Vandenbulcke K, De Vos F, Offner F, Philippé J, Apostolidis C, Molinet R, Nikula TK, Bacher K, de Gelder V, Vral A, Lahorte C, Thierens H, Dierckx RA, Slegers G. Vandenbulcke K, et al. Among authors: apostolidis c. Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1357-64. doi: 10.1007/s00259-003-1228-8. Epub 2003 Jul 3. Eur J Nucl Med Mol Imaging. 2003. PMID: 12845484
In vitro screening for synergism of high-linear energy transfer 213Bi-radiotherapy with other therapeutic agents for the treatment of B-cell chronic lymphocytic leukemia.
Vandenbulcke K, Thierens H, De Vos F, Philippé J, Offner F, Janssens A, Apostolidis C, Morgenstern A, Bacher K, de Gelder V, Dierckx RA, Slegers G. Vandenbulcke K, et al. Among authors: apostolidis c. Cancer Biother Radiopharm. 2006 Aug;21(4):364-72. doi: 10.1089/cbr.2006.21.364. Cancer Biother Radiopharm. 2006. PMID: 16999602
Targeted alpha therapy with 213Bi.
Morgenstern A, Bruchertseifer F, Apostolidis C. Morgenstern A, et al. Among authors: apostolidis c. Curr Radiopharm. 2011 Oct;4(4):295-305. doi: 10.2174/1874471011104040295. Curr Radiopharm. 2011. PMID: 22202152 Review.
Supply and Clinical Application of Actinium-225 and Bismuth-213.
Morgenstern A, Apostolidis C, Bruchertseifer F. Morgenstern A, et al. Among authors: apostolidis c. Semin Nucl Med. 2020 Mar;50(2):119-123. doi: 10.1053/j.semnuclmed.2020.02.003. Epub 2020 Feb 21. Semin Nucl Med. 2020. PMID: 32172796 Free PMC article. Review.
Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.
Buchhorn HM, Seidl C, Beck R, Saur D, Apostolidis C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Buchhorn HM, et al. Among authors: apostolidis c. Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):841-9. doi: 10.1007/s00259-006-0311-3. Epub 2007 Jan 6. Eur J Nucl Med Mol Imaging. 2007. PMID: 17206415
²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.
Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, Murphy K, Haberkorn U, Morgenstern A. Kratochwil C, et al. Among authors: apostolidis c. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19. doi: 10.1007/s00259-014-2857-9. Epub 2014 Jul 29. Eur J Nucl Med Mol Imaging. 2014. PMID: 25070685 Free PMC article.
109 results